Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain

Makoto Inoue¹, Lin Ma¹, Junken Aoki², Jerold Chun³ and Hiroshi Ueda*¹

Address: ¹Division of Molecular Pharmacology and Neuroscience, Nagasaki University, Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan, ²Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan and ³The Scripps Research Institute, 10550 North Torrey Pines Road, ICND118, La Jolla, CA 92037, USA

Email: Makoto Inoue - minoue@nagasaki-u.ac.jp; Lin Ma - dm06056d@cc.nagasaki-u.ac.jp; Junken Aoki - jaoki@mail.pharm.tohoku.ac.jp; Jerold Chun - jchun@scripps.edu; Hiroshi Ueda* - ueda@nagasaki-u.ac.jp

Abstract

Recently, we reported that lysophosphatidic acid (LPA) induces long-lasting mechanical allodynia and thermal hyperalgesia as well as demyelination and upregulation of pain-related proteins through one of its cognate receptors, LPA₁. In addition, mice lacking the LPA₁ receptor gene (lpa₁⁻/⁻ mice) lost these nerve injury-induced neuropathic pain behaviors and phenomena. However, since lpa₁⁻/⁻ mice did not exhibit any effects on the basal nociceptive threshold, it is possible that nerve injury-induced neuropathic pain and its machineries are initiated by LPA via defined biosynthetic pathways that involve multiple enzymes. Here, we attempted to clarify the involvement of a single synthetic enzyme of LPA known as autotaxin (ATX) in nerve injury-induced neuropathic pain. Wild-type mice with partial sciatic nerve injury showed robust mechanical allodynia starting from day 3 after the nerve injury and persisting for at least 14 days, along with thermal hyperalgesia. On the other hand, heterozygous mutant mice for the autotaxin gene (atx⁺/⁻), which have 50% ATX protein and 50% lysophospholipase D activity compared with wild-type mice, showed approximately 50% recovery of nerve injury-induced neuropathic pain. In addition, hypersensitization of myelinated Aδ - or Aδ-fiber function following nerve injury was observed in electrical stimuli-induced paw withdrawal tests using a Neurometer®. The hyperalgesia was completely abolished in lpa₁⁻/⁻ mice, and reduced by 50% in atx⁺/⁻ mice. Taken together, these findings suggest that LPA biosynthesis through ATX is the source of LPA for LPA₁ receptor-mediated neuropathic pain. Therefore, targeted inhibition of ATX-mediated LPA biosynthesis as well as LPA₁ receptor and its downstream pathways may represent a novel way to prevent nerve injury-induced neuropathic pain.

Findings

Lysophosphatidic acid (LPA) is a representative lipid mediator that has a variety of biological actions, including roles in cell proliferation, migration and survival via its cognate receptors LPA₁/EDG2, LPA₂/EDG4 and LPA₃/EDG7 [1-4]. Mice lacking LPA₁ receptor do not develop any signs of neuropathic pain, demyelination or upregulation of pain-related gene/protein expression following...
nerve injury [5]. Nerve injury-induced neuropathic pain and its underlying machineries are caused by a single intrathecal (i.t.) injection of LPA, and blocked by knock-down of LPA₁ receptor at the early, but not late, stage. These findings suggest that LPA₁ receptor activation initiates the machineries of neuropathic pain. Furthermore, since deletion of the LPA₁ receptor gene did not have any effect on the basal nociceptive threshold, it is evident that nerve injury-induced neuropathic pain and its machineries are initiated by LPA via defined biosynthetic pathways that involve multiple enzymes [6,7]. Therefore, targeted inhibition of LPA biosynthesis as well as LPA₁ receptor would be a valuable way to prevent nerve injury-induced neuropathic pain. Autotaxin (ATX), which was originally identified as a tumor cell motility factor, is known to have lysophospholipase D (lysoPLD) activity and convert lysophosphatidylcholine (LPC) to LPA [8,9]. Here, we report the involvement of ATX in the development of partial sciatic nerve injury-induced neuropathic pain.

Male heterozygous mutant mice for the autotaxin gene (atx⁺⁻) [10] and mutant mice for the lpa₁ gene (lpa₁⁺⁻) [11], which were backcrossed with C57BL/6 mice at least ten times before use, and their sibling wild-type mice weighing 20–24 g from the same genetic background were used. They were kept in a room maintained at 21 ± 2°C with free access to a standard laboratory diet and tap water. All procedures were approved by the Nagasaki University Animal Care Committee and complied with the recommendations of the International Association for the Study of Pain [12]. Partial ligation of the sciatic nerve of the mice was performed under pentobarbital (50 mg/kg i.p.) anesthesia, following the methods of Malmberg and Basbaum [13]. In thermal paw withdrawal tests, nociception was measured as the latency to paw withdrawal evoked by exposure to a thermal stimulus [5,14]. Unanesthetized animals were placed in plexiglas cages on top of a glass sheet and an adaptation period of 1 hour was allowed. A thermal stimulator (IITC Inc., Woodland Hills, CA, USA) was then positioned under the glass sheet and the focus of the projection bulb was aimed exactly at the middle of the plantar surface of a particular paw. Paw pressure tests were performed as described previously [5,15]. Mice were placed into a plexiglas chamber on a 6 × 6-mm wire mesh grid floor and allowed to acclimatize for 1 hour. A mechanical stimulus was then delivered onto the middle of the plantar surface of the right hind-paw using a Transducer Indicator (Model 1601; IITC Inc., Woodland Hills, CA, USA). Electrodes (Neurotron Inc., Baltimore, MD) were attached to the right plantar surface and instep of a particular paw, as previously described [16]. Transcutaneous nerve stimuli with two sine-wave pulses (250 and 2000 Hz) were applied using a Neurometer CPT/C (Neurotron Inc. Blatimore, MD, USA). The minimum intensity (µA) at which each mouse withdrew its paw was defined as the current stimulus threshold. Stimuli were applied at 10-minute intervals. Investigators blinded to the phenotype of a gene carried out all experiments. Statistical analyses were performed using Student’s t-test. Significance was set at p < 0.05.

In paw pressure tests, partial sciatic nerve injury in wild-type (atx⁺⁺) mice caused robust mechanical allodynia starting from day 3 after the nerve injury and persisting until at least day 14 (Figure 1A), consistent with a previous report [5]. There was no significant difference in the basal thresholds between heterozygous (atx⁺⁻) and wild-type (atx⁺⁺) mice. As shown in Figure 1A, the degree of mechanical allodynia was less evident in atx⁺⁻ mice than in atx⁺⁺ mice. The threshold in atx⁺⁻ mice with injury was between the level in sham-operated atx⁺⁺ mice or atx⁺⁻ mice and that in atx⁺⁺ mice with injury, and the differences from these other groups were statistically significant for at least 14 days. Similar results were observed when nerve injury-induced thermal hyperalgesia was evaluated (Figure 1B).

We previously developed a nociceptive paw-withdrawal test to evaluate nociceptive paw-withdrawal behavior in response to electrical stimuli with different frequencies in a Neurometer®, an apparatus that selectively activates sensory neurons by using sine-wave pulses of different frequencies [16]. As shown in Figure 1C (left panel), the threshold for paw withdrawal upon 2000-Hz electrical stimulation, which is supposed to stimulate Aβ fibers, was approximately 320 µA in wild-type lpa₁⁺⁺ mice. Partial sciatic nerve injury in wild-type (lpa₁⁺⁺) mice caused a significant decrease in the withdrawal threshold to 2000 µA at day 7, which persisted until day 14 (Figure 1C, left panel). Although there was no significant difference in the basal thresholds between knockout mice (lpa₁⁻⁻ mice) and wild-type mice, the hypersensitivity was completely abolished at days 7 and 14 in lpa₁⁺⁻ mice. On the other hand, the hypersensitivity to 2000-Hz electrical stimulation at day 14 after the nerve injury was partially, but significantly, attenuated in atx⁺⁻ mice, which showed no significant change in the threshold without injury (Figure 1D, left panel). Quite similar results were observed when the withdrawal responses induced by 250-Hz electrical stimulation, which is supposed to stimulate Aδ fibers, were evaluated in lpa₁⁻⁻ mice and atx⁻⁻ mice with and without nerve injury (Figure 1C and 1D, right panels).

In the present study, we used atx⁺⁻ heterozygous mutant mice, since atx⁺⁻ homozygous mutant mice were reported to die at the early stage of embryogenesis [10]. Therefore, these heterozygous mice are expected to have half the level of ATX expression, and indeed they were reported to show 50% lysoPLD activity relative to wild-type mice [10]. This finding is consistent with the present study, in
Partial blockade of neuropathic pain in $\text{atx}^{+/\pm}$ mice. (A, B) Partial blockade of mechanical allodynia and hyperalgesia in $\text{atx}^{+/\pm}$ mice. Paw pressure tests (A) were carried out on days 3, 7 and 14 after the nerve injury, while thermal paw withdrawal tests (B) were carried out on day 14 after the nerve injury. (C, D) Complete and partial blockade of $\text{A}^\beta$ (2000 Hz)- and $\text{A}^\delta$ (250 Hz)-fiber stimulation-induced hypersensitivities in $\text{lpa}^{+/\pm}$ (C) and $\text{atx}^{+/\pm}$ (D) mice, respectively. Behavior experiments were carried out on days 7 and 14 (C) and day 14 (D) after the nerve injury. All data represent the mean ± SEM from 5–6 separate experiments. $^* p < 0.05$ compared with sham-operated mice; $^# p < 0.05$ compared with wild-type mice with nerve injury.
which \textit{atx}+/− heterozygous mice showed partial attenuation of nerve injury-induced neuropathic pain, as observed for conventional mechanical allodynia and thermal hyperalgesia (Figure 1A), which are mediated through LPA1 receptor activation [5].

On the other hand, nerve injury is known to cause functional changes in myelinated A-fibers, such as demyelination, and upregulation of Ca\(^{2+}\)-channel α2δ-1 subunits and sodium channels in medium/large neurons of the dorsal root ganglion would underlie the molecular mechanisms for neuropathic pain. Previously, we demonstrated that nerve injury causes hypersensitization of myelinated Aβ- and Aδ-fiber functions in an electrical stimuli-induced paw flexion (EPF) test, which is a modified EPW test [17]. Here, we found that hypersensitization of myelinated Aβ- and Aδ-fiber functions following nerve injury was observed in the EPW test, and mediated through LPA1 receptor activation (Figure 1C). Consequently, we carried out further tests to clarify the involvement of ATX in Aβ- and Aδ-fiber hypersensitization. The \textit{atx}+/− heterozygous mice showed significant and partial attenuation of these phenomena. It is well known that LPA is mainly produced via two major pathways, namely LPC conversion mediated by activation of ATX and phosphatidic acid conversion mediated by activation of phospholipase A\(_2\) (PLA\(_2\)) [6,7]. However, all the findings in the present report suggest that nerve injury-induced LPA production mainly occurs through LPC conversion mediated by activation of ATX.

There are reports that LPC is produced under physiological and pathological conditions [18,19]. Furthermore, LPC treatment of the saphenous or sciatic nerve induced neuropathic pain-like behaviors, such as mechanical allodynia and thermal hyperalgesia, as well as demyelination and upregulation of pain-related proteins in the dorsal root ganglion [20]. More recently, we found that i.t. injection of LPC induces neuropathic pain-like behaviors through ATX-LPA1 receptor signaling, since these behaviors were completely abolished in \textit{lpa}\(_1\)/−/− mice and partially blocked in \textit{atx}\(_1\)/−/− heterozygous mutant mice [21]. Therefore, LPC is involved in neuropathic pain.

We previously reported that i.t. injection of an antisense oligonucleotide for LPA\(_1\) receptor or inhibitors of RhôA/ROCK, one of the downstream signaling molecules of LPA\(_1\) receptor, completely abolished nerve injury-induced neuropathic pain [5]. Furthermore, i.t. injection of LPA mimics nerve injury-induced neuropathic pain. Therefore, nerve injury seems to cause LPC production in the spinal cord. ATX protein is present in the cerebrospinal fluid (CSF) and has lysoPLD activity to convert LPC into LPA [22]. On the other hand, LPC is not present in CSF [22]. Therefore, nerve injury would produce LPC in the spinal cord, which would subsequently be hydrolyzed by ATX to form LPA. Experiments to evaluate LPA and LPC production following nerve injury and clarify the relationship of ATX to LPA production are the next important issues to be addressed.

In addition to the lysoPLD activity to convert LPC to LPA, ATX also possesses activity to convert sphingosylphosphorylcholine to bioactive sphingosine-1-phosphate [23]. However, we previously reported that i.t. injection of sphingosine-1-phosphate did not cause neuropathic pain-like allodynia or hyperalgesia [5]. These findings suggest that the marked reduction of neuropathic pain in \textit{atx}+/− mice can be attributed to a reduction in LPA production following nerve injury.

In summary, we have demonstrated that LPA biosynthesis by ATX is the source of LPA for LPA\(_1\) receptor-mediated neuropathic pain. Therefore, targeted inhibition of ATX-mediated LPA biosynthesis as well as LPA\(_1\) receptor and its downstream pathways may represent a novel way to prevent nerve injury-induced neuropathic pain.

### Acknowledgements
This work was supported by MEXT KAKENHI (17I09015 to HU; 18689010 to MI) and an NIH grant (NS048478 to JC).

### References

1. Tigyi G, Miledi R: Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. The Journal of biological chemistry 1992, 267:21360-21367.

2. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan MM: Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 2003, 5:38-45.

3. Jalink K, Eichholz T, Postma FR, van Corven EJ, Moolenaar WH: Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ 1993, 4:247-255.

4. Fukushima N, Weiner JA, Chun J: Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol 2000, 228:6-18.

5. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10:712-718.

6. Aoki J: Mechanisms of lysophosphatidic acid production. Seminars in cell & developmental biology 2004, 15:477-489.

7. van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Progress in lipid research 2007, 46:145-160.

8. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. The Journal of biological chemistry 2002, 277:39436-39442.

9. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohhma N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233.

10. Tanaka M, Okuda S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatsushiro Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. The Journal of biological chemistry 2006, 281:25822-25830.
11. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J: Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:13384-13389.

12. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.

13. Malmberg AB, Basbaum AI: Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 1998, 76:215-222.

14. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.

15. Rashid MH, Inoue M, Kondo S, Kawashima T, Bakoshi S, Ueda H: Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther 2003, 304:940-948.

16. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H: Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther 2006, 318:735-740.

17. Matsumoto M, Inoue M, Hald A, Yamaguchi A, Ueda H: Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol Pain 2006, 2:16.

18. Yokota T, Hansson GK: Immunological mechanisms in atherosclerosis. Journal of internal medicine 1995, 238:479-489.

19. Murugesan G, Fox PL: Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. The Journal of clinical investigation 1996, 97:2736-2744.

20. Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM: Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 2003, 23:3221-3233.

21. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H: Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 2008. Epub ahead of print.

22. Sato K, Malchinkhuu E, Muraki T, Ishikawa K, Hayashi K, Tosaka M, Mochiduki A, Inoue K, Tomura H, Mogi C, Nochi H, Tamoto K, Oka-Jima F: Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem 2005, 92:904-914.

23. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML: Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 2003, 63:5446-5453.